Latest filing published 27 Dec 2021 for Ziopharm Oncology INC, €23k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Eleanor De Groot: trading record in brief
Eleanor De Groot (senior executive) discloses dealings in Alaunos Therapeutics, Inc. to SEC (Form 4). In total, 5 filings cover trades dated from 2 January 2020 to 22 December 2021.
On the market, this insider has only sold: 3 sales, €172k in total. Other entries cover 2 share grants. So far in 2021, the count stands at no purchases and 2 sales.
The newest entry dates from 27 December 2021: an open-market sale of €23k, in Alaunos Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Eleanor De Groot
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 20,132 shares@ US$1.27100.0% of flowCommon StockSEC:0000899243-21-049739:0
1 of 1 declaration